Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its use is hindered by the recently expressed safety concerns. One approach for reducing SOR toxicity is to use lower doses in combination with other less toxic agents. Biochanin-A (Bio-A), a promising isoflavon...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef , Mohieldin M., Tolba, Mai F., Badawy, Noha N., Liu, Andrew W., El-Ahwany, Eman, Khalifa, Amani E., Zada, Suher, Abdel-Naim, Ashraf B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965826/
https://www.ncbi.nlm.nih.gov/pubmed/27470322
http://dx.doi.org/10.1038/srep30717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965826/
https://www.ncbi.nlm.nih.gov/pubmed/27470322
http://dx.doi.org/10.1038/srep30717

Ejemplares similares